AB0207 VOLATILITY OF WORK PARTICIPATION DOMAINS AFTER A FLARE OF RHEUMATOID ARTHRITIS UNDER TREAT-TO-TARGET THERAPY

Background Rheumatoid arthritis (RA) is one of the most common diseases worldwide with a need for rehabilitation despite recent advantages in pharmacological treatment options. Furthermore, data show numerical increase years life disability RA patients Germany from 1990 to 2017. Limitations work participation (WP) also remain highly prevalent. Objectives We investigate development different domains WP (unimpaired WP, presenteeism, absenteeism, and no employment) at patient level under drug therapy over 12 months understand impact treatment. Methods The multicenter ERFASS study prospectively enrolled seropositive an active flare disease initiating treat-to-target (T2T) [1]. Patients were between 01/2018 12/2019. examine working-age (18-65 years) excluding students old-age pensioners using WPAI complete dataset all three measurement time points (month 0, 6 12). Disease activity was measured DAS28. Results A total 122 (73.0% female) mean age 52.8 (SD: 8.5) included. according DAS28-CRP decreased significantly course 4.2 baseline 2.5 month (p<.001). proportion non-working increased numerically 30.3% 36.1% (p=0.085). absenteeism 22.1% 12.3% (p=0.033). There small changes presenteeism 12: 35.2%; p=0.086). unrestricted 10.7% 16.4% (p<0.001) (Table 1). Graph 1 shows quantitatively relevant sankey diagram. group not working mainly gains growth absenteeism. unimpaired proportionally become more because or improve their WP. However, we detected substantial initially facing impairments as likely during T2T. At measure see fluctuations Conclusion Besides good response terms activity, demonstrate that majority unemployed acute does find way back into force within twelve T2T pharmaceutical greatest improvements observed baseline. Although without limitations significantly, it remained low end study. Our provide understanding after which helps tailor occupational concepts. Reference [1]Hoeper, J. R., et al. (2021). Effect nurse-led care on outcomes APCA/RF-positive rheumatoid undergoing treat-to-target. RMD Open. Table 1. Demographics, course. Baseline Month p-value Age (SD) (8.5) Gender (female) n (%) 89 (73.0) (mean) 2.8 <.001 Not 37 (30.3) 40 (32.8) 44 (36.1) .085 Absenteeism 27 (22.1) 16 (13.1) 15 (12.3) .033 Presenteeism only 45 (36.9) 50 (41.0) 43 (35.3) .086 Unimpaired 13 (10.7) 20 (16.4) Development Sankey width arrows equivalents changing groups. Acknowledgements: NIL. Disclosure Interests Sara Eileen Meyer: None declared, Juliana Rachel Hoeper: Birte Luise Haegermann: Ioana Iliadis: Torsten Witte Grant/research support from: Abbvie, Novartis, Kai Kahl: Kirsten Hoeper Speakers bureau: Galapagos, Consultant of: Dirk Meyer-Olson Amgen, Berlin Chemie, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Cellgene, Celltrion, Chugai, Fresenius Kabi, GSK, Jansen Cilag, Lilly, Medac, Merck Sharp & Dome, Mylan, Pfizer, Sandoz Hexal, Sanofi und UCB, UCB.